Literature DB >> 23959173

Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivity.

Liang Wang, Matthew R Brier, Abraham Z Snyder, Jewell B Thomas, Anne M Fagan, Chengjie Xiong, Tammie L Benzinger, David M Holtzman, John C Morris, Beau M Ances.   

Abstract

IMPORTANCE: Resting-state functional connectivity magnetic resonance imaging has great potential for characterizing pathophysiological changes during the preclinical phase of Alzheimer disease.
OBJECTIVE: To assess the relationship between default mode network integrity and cerebrospinal fluid biomarkers of Alzheimer disease pathology in cognitively normal older individuals. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional cohort study at The Charles F. and Joanne Knight Alzheimer's Disease Research Center at Washington University in St Louis, St Louis, Missouri, among 207 older adults with normal cognition (Clinical Dementia Rating, 0). MAIN OUTCOMES AND MEASURES: Resting-state functional connectivity magnetic resonance imaging measures of default mode network integrity.
RESULTS: Decreased cerebrospinal fluid Aβ42 and increased cerebrospinal fluid phosphorylated tau181 were independently associated with reduced default mode network integrity, with the most prominent decreases in functional connectivity observed between the posterior cingulate and medial temporal regions. Observed reductions in functional connectivity were unattributable to age or structural atrophy in the posterior cingulate and medial temporal areas. Similar resting-state functional connectivity magnetic resonance imaging findings in relation to cerebrospinal fluid biomarkers were obtained using region-of-interest analyses and voxelwise correlation mapping. CONCLUSIONS AND RELEVANCE: Both Aβ and tau pathology affect default mode network integrity before clinical onset of Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23959173      PMCID: PMC3836828          DOI: 10.1001/jamaneurol.2013.3253

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  49 in total

1.  "Preclinical" AD revisited: neuropathology of cognitively normal older adults.

Authors:  F A Schmitt; D G Davis; D R Wekstein; C D Smith; J W Ashford; W R Markesbery
Journal:  Neurology       Date:  2000-08-08       Impact factor: 9.910

Review 2.  Resting-state functional connectivity in neuropsychiatric disorders.

Authors:  Michael Greicius
Journal:  Curr Opin Neurol       Date:  2008-08       Impact factor: 5.710

Review 3.  The brain's default network: anatomy, function, and relevance to disease.

Authors:  Randy L Buckner; Jessica R Andrews-Hanna; Daniel L Schacter
Journal:  Ann N Y Acad Sci       Date:  2008-03       Impact factor: 5.691

4.  Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease.

Authors:  J L Price; A I Ko; M J Wade; S K Tsou; D W McKeel; J C Morris
Journal:  Arch Neurol       Date:  2001-09

5.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

Authors:  Trey Sunderland; Gary Linker; Nadeem Mirza; Karen T Putnam; David L Friedman; Lida H Kimmel; Judy Bergeson; Guy J Manetti; Matthew Zimmermann; Brian Tang; John J Bartko; Robert M Cohen
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

6.  Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory.

Authors:  Ganesh M Shankar; Shaomin Li; Tapan H Mehta; Amaya Garcia-Munoz; Nina E Shepardson; Imelda Smith; Francesca M Brett; Michael A Farrell; Michael J Rowan; Cynthia A Lemere; Ciaran M Regan; Dominic M Walsh; Bernardo L Sabatini; Dennis J Selkoe
Journal:  Nat Med       Date:  2008-06-22       Impact factor: 53.440

7.  Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly.

Authors:  Yvette I Sheline; Marcus E Raichle; Abraham Z Snyder; John C Morris; Denise Head; Suzhi Wang; Mark A Mintun
Journal:  Biol Psychiatry       Date:  2009-10-14       Impact factor: 13.382

8.  Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred.

Authors:  Pau Pastor; Catherine M Roe; Andrés Villegas; Gabriel Bedoya; Sumi Chakraverty; Gloria García; Victoria Tirado; Joanne Norton; Silvia Ríos; Maribel Martínez; Kenneth S Kosik; Francisco Lopera; Alison M Goate
Journal:  Ann Neurol       Date:  2003-08       Impact factor: 10.422

9.  Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease.

Authors:  Anne M Fagan; Mark A Mintun; Aarti R Shah; Patricia Aldea; Catherine M Roe; Robert H Mach; Daniel Marcus; John C Morris; David M Holtzman
Journal:  EMBO Mol Med       Date:  2009-11       Impact factor: 12.137

10.  Disruption of functional connectivity in clinically normal older adults harboring amyloid burden.

Authors:  Trey Hedden; Koene R A Van Dijk; J Alex Becker; Angel Mehta; Reisa A Sperling; Keith A Johnson; Randy L Buckner
Journal:  J Neurosci       Date:  2009-10-07       Impact factor: 6.167

View more
  43 in total

1.  Cerebrospinal fluid Aβ42 moderates the relationship between brain functional network dynamics and cognitive intraindividual variability.

Authors:  Karin L Meeker; Beau M Ances; Brian A Gordon; Cort W Rudolph; Patrick Luckett; David A Balota; John C Morris; Anne M Fagan; Tammie L Benzinger; Jill D Waring
Journal:  Neurobiol Aging       Date:  2020-11-02       Impact factor: 4.673

2.  Unrecognized preclinical Alzheimer disease confounds rs-fcMRI studies of normal aging.

Authors:  Matthew R Brier; Jewell B Thomas; Abraham Z Snyder; Liang Wang; Anne M Fagan; Tammie Benzinger; John C Morris; Beau M Ances
Journal:  Neurology       Date:  2014-09-26       Impact factor: 9.910

3.  Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals.

Authors:  Aaron P Schultz; Jasmeer P Chhatwal; Trey Hedden; Elizabeth C Mormino; Bernard J Hanseeuw; Jorge Sepulcre; Willem Huijbers; Molly LaPoint; Rachel F Buckley; Keith A Johnson; Reisa A Sperling
Journal:  J Neurosci       Date:  2017-03-17       Impact factor: 6.167

4.  CSF proteins and resting-state functional connectivity in Parkinson disease.

Authors:  Meghan C Campbell; Jonathan M Koller; Abraham Z Snyder; Chandana Buddhala; Paul T Kotzbauer; Joel S Perlmutter
Journal:  Neurology       Date:  2015-05-15       Impact factor: 9.910

Review 5.  Network dysfunction in Alzheimer's disease: refining the disconnection hypothesis.

Authors:  Matthew R Brier; Jewell B Thomas; Beau M Ances
Journal:  Brain Connect       Date:  2014-06

6.  Alteration of the regional cerebral glucose metabolism in healthy subjects by glucose loading.

Authors:  Kenji Ishibashi; Kei Wagatsuma; Kiichi Ishiwata; Kenji Ishii
Journal:  Hum Brain Mapp       Date:  2016-04-08       Impact factor: 5.038

7.  Evaluating resting-state BOLD variability in relation to biomarkers of preclinical Alzheimer's disease.

Authors:  Peter R Millar; Beau M Ances; Brian A Gordon; Tammie L S Benzinger; Anne M Fagan; John C Morris; David A Balota
Journal:  Neurobiol Aging       Date:  2020-08-18       Impact factor: 4.673

Review 8.  The evolution of preclinical Alzheimer's disease: implications for prevention trials.

Authors:  Reisa Sperling; Elizabeth Mormino; Keith Johnson
Journal:  Neuron       Date:  2014-11-05       Impact factor: 17.173

9.  Functional connectivity and graph theory in preclinical Alzheimer's disease.

Authors:  Matthew R Brier; Jewell B Thomas; Anne M Fagan; Jason Hassenstab; David M Holtzman; Tammie L Benzinger; John C Morris; Beau M Ances
Journal:  Neurobiol Aging       Date:  2013-10-18       Impact factor: 4.673

10.  Relationship between Stroop performance and resting state functional connectivity in cognitively normal older adults.

Authors:  Janet M Duchek; David A Balota; Jewell B Thomas; Abraham Z Snyder; Patrick Rich; Tammie L Benzinger; Anne M Fagan; David M Holtzman; John C Morris; Beau M Ances
Journal:  Neuropsychology       Date:  2013-09       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.